Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: Correlations with clinical variables

Neurologia Medico-Chirurgica

Volumn 52, Issue 8, 2012, Pages 563-569

  Matsuyama, Junko ^a,b,c  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Minamisoma City General Hospital   (Japan)

Author keywords

MIB 1 labeling index; Pituitary adenoma; Progression; Receiver operating characteristic analysis; Residual adenoma

Indexed keywords

KI 67 ANTIGEN;

ACTH SECRETING ADENOMA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CAVERNOUS SINUS; CLINICAL ARTICLE; CRANIOTOMY; FEMALE; GONADOTROPH ADENOMA; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; MINIMAL RESIDUAL DISEASE; POSTOPERATIVE PERIOD; PROGNOSIS; PROLACTINOMA; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; THYROTROPIN SECRETING ADENOMA; TRANSSPHENOIDAL SURGERY; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ADENOMA; ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865520328     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.52.563     Document Type: Article

References (34)

1. Abe T, Sanno N, Osamura YR, Matsumoto K: Proliferative potential in pituitary adenomas: Measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien) 139: 613-618, 1997
2. Chacko G, Chacko A, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS: The clinical significance ofMIB-1 labeling index in pituitary adenomas. Pituitary 13: 337-344, 2010
3. Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell KR, Wilson CB, Kunwar S: Longterm recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108: 736-745, 2008
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds): World Health Organization Classification of Tumors: Tumours of Endocrine Organs. Lyon, IARC, 2004, pp 10-47
5. Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V: Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157: 141-147, 2007
6. Eng J: Receiver operating characteristic analysis: a primer. Acad Radiol 12: 909-916, 2005
7. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maria G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L: Prognostic Significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93: 2746-2750, 2008
8. Gejman R, Swearingen B, Hedley-Whyte ET: Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39: 758-766, 2008
9. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Moä nting J, Renicke M: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99: 674-679, 2003
10. Hsu D, Hakim F, Biller BMK, De La Monte S, Zervas NT, Klibanski A, Hedley-Whyte T: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753-761, 1993
11. Ichihara K: [Problems related to determination of reference interval and clinical decision limit in enzyme immunoassay]. Nihon Rinsho 53: 2220-2230, 1995 (Japanese)
12. Iuchi T, Saeki N, Osato K, Yamaura A: Proliferation, vascular endothelial growth expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142: 1345-1351, 2000
13. Jaffrain-ReaML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Succhi LF, Gulino A, Cantore G: A critical reappraisal ofMIB-1 labeling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9: 103-113, 2002
14. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T: Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136: 37-43, 1995
15. Knosp E, Kitz K, Perneczky A: Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25: 927-930, 1989
16. Knosp E, Steiner E, Kitz K, Matula CH: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-618, 1993
17. Landolt AM, Shibata T, Kleihues P: Growth rate of human pituitary adenomas. J Neurosurg 67: 803-806, 1987
18. Laws ER Jr, Lopes MB: The new WHO classification of pituitary tumors: Highlights and areas of controversy. Acta Neuropathol 111: 80-81, 2006
19. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M: Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108: 525-532, 2008
20. Miyagami M, Nakamura S: [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas]. No To Shinkei 50: 27-32, 1998 (Japanese)
21. Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T: MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139: 426-432, 1997
22. Ogawa Y, Ikeda H, Tominaga T: Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%. J Endocrinol Invest 32: 581-584, 2009
23. Picozzi P, Losa M, Mortini P, Valle MA, Franzin A, Attuati L, Ferrari da Passano C, Giovanelli M: Radiosurgery and the prevention of regrowth of incompletely removed nonfunctioning pituitary adenomas. J Neurosurg 102 Suppl: 71-74, 2005
24. Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP: Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37: 235-243, 2004
25. Saeger W, Luä decke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156: 203-216, 2007
26. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, CusimanoM: Ki-67 in pituitary neoplasms: a review-part I. Neurosurgery 65: 429-437, 2009
27. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WJ Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-353, 2006
28. Suzuki M, Minematsu T, Oyama K, Tahara S, Miyai S, Sanno N, Osamura RY, Teramoto A: Expression of proliferation markers in human pituitary incidentalomas. Endocr Pathol 17: 263-275, 2006
29. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S: Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98: 359-365, 2003
30. Thapar K, Kovacs K, Scheihauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-107, 1996
31. Thapar K, Scheihauer BW, Kovacs K, Pernicone PJ, Laws ER: P53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765-771, 1996
32. Widhalm G, Wolfsberger S, Presser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E: Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111: 563-571, 2009
33. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 6: 580-585, 2007
34. Zada G, WoodmanseeWW, Ramkissoon A, Amadio J, Nose V, Laws ER: Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114: 336-344, 2011